Formycon says Keytruda biosimilar candidate FYB206 showed pharmacokinetic equivalence in DAHLIA trial

Formycon highlighted a peer-reviewed BioDrugs publication detailing its streamlined clinical program for Keytruda biosimilar candidate FYB206. The pivotal DAHLIA trial showed FYB206 matched Keytruda in pharmacokinetics, supporting biosimilarity without a traditional efficacy study.